Sangamo Therapeutics Statistics
Share Statistics
Sangamo Therapeutics has 208.65M shares outstanding. The number of shares has increased by 2.44% in one year.
| Shares Outstanding | 208.65M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.2% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 199.18M |
| Failed to Deliver (FTD) Shares | 43.40K |
| FTD / Avg. Volume | 0.41% |
Short Selling Information
The latest short interest is 19.61M, so 9.4% of the outstanding shares have been sold short.
| Short Interest | 19.61M |
| Short % of Shares Out | 9.4% |
| Short % of Float | 9.84% |
| Short Ratio (days to cover) | 3.54 |
Valuation Ratios
The PE ratio is -0.37 and the forward PE ratio is -11.41.
| PE Ratio | -0.37 |
| Forward PE | -11.41 |
| PS Ratio | 0.54 |
| Forward PS | 2.4 |
| PB Ratio | 1.14 |
| P/FCF Ratio | -0.39 |
| PEG Ratio | n/a |
Enterprise Valuation
Sangamo Therapeutics Inc. has an Enterprise Value (EV) of 132.88M.
| EV / Earnings | -0.52 |
| EV / Sales | 0.75 |
| EV / EBITDA | -1.52 |
| EV / EBIT | -0.48 |
| EV / FCF | -0.54 |
Financial Position
The company has a current ratio of 1.98, with a Debt / Equity ratio of 0.46.
| Current Ratio | 1.98 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.46 |
| Total Debt / Capitalization | 31.49 |
| Cash Flow / Debt | -5.9 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -3.11% and return on capital (ROIC) is -222.1%.
| Return on Equity (ROE) | -3.11% |
| Return on Assets (ROA) | -1.56% |
| Return on Capital (ROIC) | -222.1% |
| Revenue Per Employee | 435.14K |
| Profits Per Employee | -636.62K |
| Employee Count | 405 |
| Asset Turnover | 1.07 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -5.07M |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by 118.28% in the last 52 weeks. The beta is 1.1, so Sangamo Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.1 |
| 52-Week Price Change | 118.28% |
| 50-Day Moving Average | 2.04 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 33.37 |
| Average Volume (20 Days) | 10.48M |
Income Statement
In the last 12 months, Sangamo Therapeutics had revenue of 176.23M and earned -257.83M in profits. Earnings per share was -1.48.
| Revenue | 176.23M |
| Gross Profit | -45.33M |
| Operating Income | -274.00M |
| Net Income | -257.83M |
| EBITDA | -87.43M |
| EBIT | -274.00M |
| Earnings Per Share (EPS) | -1.48 |
Balance Sheet
The company has 45.20M in cash and 38.10M in debt, giving a net cash position of 7.10M.
| Cash & Cash Equivalents | 45.20M |
| Total Debt | 38.10M |
| Net Cash | 7.10M |
| Retained Earnings | -1.41B |
| Total Assets | 111.26M |
| Working Capital | 14.97M |
Cash Flow
In the last 12 months, operating cash flow was -224.84M and capital expenditures -21.16M, giving a free cash flow of -246.00M.
| Operating Cash Flow | -224.84M |
| Capital Expenditures | -21.16M |
| Free Cash Flow | -246.00M |
| FCF Per Share | -1.41 |
Margins
Gross margin is -25.72%, with operating and profit margins of -155.48% and -146.3%.
| Gross Margin | -25.72% |
| Operating Margin | -155.48% |
| Pretax Margin | -149.18% |
| Profit Margin | -146.3% |
| EBITDA Margin | -49.61% |
| EBIT Margin | -155.48% |
| FCF Margin | -139.59% |
Dividends & Yields
SGMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -145.1% |
| FCF Yield | -115.59% |
Analyst Forecast
The average price target for SGMO is $3, which is 194.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 194.1% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -19.62 |
| Piotroski F-Score | 2 |